Optimizing biological therapy in Crohn's disease

Krisztina Barbara Gecse, Zsuzsanna Végh, Péter László Lakatos

Research output: Contribution to journalReview article

10 Citations (Scopus)


Anti-TNF therapy has revolutionized the treatment of inflammatory bowel diseases, including both Crohn's disease and ulcerative colitis. However, a significant proportion of patients does not respond to anti-TNF agents or lose response over time. Recently, therapeutic drug monitoring has gained a major role in identifying the mechanism and management of loss of response. The aim of this review article is to summarize the predictors of efficacy and outcomes, the different mechanisms of anti-TNF/biological failure in Crohn's disease and identify strategies to optimize biological treatment.

Original languageEnglish
Pages (from-to)37-45
Number of pages9
JournalExpert Review of Gastroenterology and Hepatology
Issue number1
Publication statusPublished - Jan 1 2016


  • Crohn's disease
  • Therapeutic drug level monitoring
  • Ulcerative colitis
  • adalimumab
  • infliximab

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Optimizing biological therapy in Crohn's disease'. Together they form a unique fingerprint.

  • Cite this